Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Inside the Ben Johnson hiring: What convinced him Chicago Bears are ‘set up for success’ — and how they were ‘ready to pounce’
The interview was scheduled for Jan. 11. The Detroit Lions were deep into their postseason bye week and still awaiting their ...
Ben Johnson named a finalist for AP Assistant Coach of the Year
New Chicago Bears head coach Ben Johnson has been named a finalist for AP Assistant Coach of the Year following his 2024 season as the Detroit Lions offensive coordinator.
Johnson & Johnson price target lowered to $158 from $160 at Bernstein
Bernstein analyst Lee Hambright lowered the firm’s price target on Johnson & Johnson to $158 from $160 and keeps a Market Perform rating on ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Anti-aging fanatic Bryan Johnson slammed for ‘gross’ post tracking son’s erection data
The 47-year-old millionaire tech mogul posted screenshots showing data from an overnight erection-tracking machine for both himself and his 19-year-old son, Talmage.